CA2834829A1 - Solvate de dimethylformamide rifaximine - Google Patents
Solvate de dimethylformamide rifaximine Download PDFInfo
- Publication number
- CA2834829A1 CA2834829A1 CA2834829A CA2834829A CA2834829A1 CA 2834829 A1 CA2834829 A1 CA 2834829A1 CA 2834829 A CA2834829 A CA 2834829A CA 2834829 A CA2834829 A CA 2834829A CA 2834829 A1 CA2834829 A1 CA 2834829A1
- Authority
- CA
- Canada
- Prior art keywords
- rifaximin
- solvate
- hours
- dimethylformamide
- process according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 title claims abstract description 58
- 229960003040 rifaximin Drugs 0.000 title claims abstract description 57
- 239000012453 solvate Substances 0.000 title claims abstract description 47
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 title claims description 93
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 239000011541 reaction mixture Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000007787 solid Substances 0.000 description 4
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 238000000113 differential scanning calorimetry Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000002411 thermogravimetry Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000007386 hepatic encephalopathy Diseases 0.000 description 2
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 229940064406 xifaxan Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1289/DEL/2011 | 2011-05-02 | ||
| IN1289DE2011 | 2011-05-02 | ||
| PCT/IB2012/052200 WO2012150561A1 (fr) | 2011-05-02 | 2012-05-02 | Solvate de diméthylformamide rifaximine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2834829A1 true CA2834829A1 (fr) | 2012-11-08 |
Family
ID=46124584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2834829A Abandoned CA2834829A1 (fr) | 2011-05-02 | 2012-05-02 | Solvate de dimethylformamide rifaximine |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP2705042A1 (fr) |
| AU (1) | AU2012251385A1 (fr) |
| CA (1) | CA2834829A1 (fr) |
| WO (1) | WO2012150561A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1698630T3 (da) | 2005-03-03 | 2014-12-08 | Alfa Wassermann Spa | Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater |
| US9018684B2 (en) | 2009-11-23 | 2015-04-28 | California Institute Of Technology | Chemical sensing and/or measuring devices and methods |
| IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
| CA2876737A1 (fr) | 2012-06-13 | 2013-12-19 | Apotex Pharmachem Inc. | Formes polymorphes de rifaximine |
| ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
| ES2829285T3 (es) | 2013-04-12 | 2021-05-31 | Alfasigma Spa | Administración de AINE y composiciones, métodos y sistemas relacionados |
| EP2927235B1 (fr) | 2014-03-31 | 2017-02-08 | Euticals S.P.A. | Mélange de polymorphes de rifaximine et son utilisation pour la préparation de formulations solides |
| PL3143027T3 (pl) | 2014-05-12 | 2019-11-29 | Alfasigma Spa | Nowe solwatowane krystaliczne postaci rifaksyminy, ich wytwarzanie, kompozycje i zastosowania |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1154655B (it) | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
| IT1199374B (it) | 1984-05-15 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
| ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
| US7902206B2 (en) | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
| DK1698630T3 (da) | 2005-03-03 | 2014-12-08 | Alfa Wassermann Spa | Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater |
| US8633234B2 (en) | 2006-09-22 | 2014-01-21 | Cipla Limited | Rifaximin |
| US7709634B2 (en) | 2007-09-20 | 2010-05-04 | Apotex Pharmachem Inc. | Amorphous form of rifaximin and processes for its preparation |
| SG10201607926VA (en) * | 2008-02-25 | 2016-11-29 | Salix Pharmaceuticals Ltd | Forms of rifaximin and uses thereof |
| US8486956B2 (en) * | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
| US8513275B2 (en) * | 2010-06-03 | 2013-08-20 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
-
2012
- 2012-05-02 AU AU2012251385A patent/AU2012251385A1/en not_active Abandoned
- 2012-05-02 WO PCT/IB2012/052200 patent/WO2012150561A1/fr not_active Ceased
- 2012-05-02 CA CA2834829A patent/CA2834829A1/fr not_active Abandoned
- 2012-05-02 EP EP12721936.8A patent/EP2705042A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012150561A1 (fr) | 2012-11-08 |
| AU2012251385A1 (en) | 2013-11-21 |
| EP2705042A1 (fr) | 2014-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2834829A1 (fr) | Solvate de dimethylformamide rifaximine | |
| JP7346353B2 (ja) | リファキシミン | |
| US8883795B2 (en) | Polymorphic forms of Rifaximin | |
| EP3664805A1 (fr) | Polymorphes et co-cristaux de roxadustat | |
| EP4180435A1 (fr) | Forme cristalline d'upadacitinib, son procédé de préparation et son utilisation | |
| WO2020053660A1 (fr) | Formes solides d'un inhibiteur de bet | |
| CN111777595A (zh) | 一种环己烷甲酰胺类化合物的新晶型及其制备方法 | |
| WO2010070677A2 (fr) | Procédé de préparation de prasugrel et de ses sels pharmaceutiquement acceptables | |
| WO2013027227A1 (fr) | Nouvelle forme polymorphe i de la rifaximine | |
| EP2262786A2 (fr) | Formes de colchicine à l état solide, procédés de fabrication et procédés d utilisation associés | |
| US7745429B2 (en) | Crystal forms of olanzapine and processes for their preparation | |
| JP2016533361A (ja) | ピラゾロピリジン化合物の固体形態 | |
| KR102205843B1 (ko) | 9-아미노메틸 치환된 테트라사이클린 화합물의 결정형 및 그것의 제조 방법 | |
| EP3473623B1 (fr) | Formes cristallines de nbi-98854, procédé de préparation s'y rapportant et utilisation associée | |
| CA2596754C (fr) | Melange 1h-imidazo[4,5-b]pyridin-5-amine:sulfate de 7-[5-[(cyclohexylmethylamino)methyl]-1h-indol-2-yl]-2-methyle a (1:1) trihydrate sous forme de cristaux et utilisations pour letraitement de maladies et desordres inflammatoires, autoimmunes et proliferants | |
| CN113045554A (zh) | 一种非索替尼晶型及其制备方法 | |
| EP3327007A1 (fr) | Azine-fumarate à orbitale, hydrate, forme cristalline et leur procédé de préparation | |
| CN110730785B (zh) | 一种脂肪酸胆汁酸偶合物的晶型及其制备方法和用途 | |
| Suzuki et al. | Studies on mechanism of thermal crystal transformation of sitafloxacin hydrates through melting and recrystallization, yielding different anhydrates depending on initial crystalline forms | |
| WO2024214044A1 (fr) | Complexes multicomposants comprenant des sels, des hydrates et des solvates d'inupadenant | |
| JP2008540449A (ja) | （２ｅ，４ｓ）−４−［（ｎ−｛［（２ｒ）−１−イソプロピルピペリジン−２−イル］−カルボニル｝−３−メチル−ｌ−バリル）（メチル）アミノ］−２，５−ジメチルヘキサ−２−エン酸の非溶媒和およびホストゲスト溶媒和結晶フォーム、およびそれらの医薬的使用 | |
| CA2884248A1 (fr) | Nouveaux polymorphes d'azilsartan | |
| WO2014024210A2 (fr) | Nouveaux polymorphes du doxercalciférol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20131031 |
|
| FZDE | Dead |
Effective date: 20160504 |